These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 9381303)

  • 41. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma.
    Phillips GL; Meisenberg BR; Reece DE; Adams VR; Badros AZ; Brunner JL; Fenton RG; Filicko J; Grosso DL; Hale GA; Howard DS; Johnson VP; Kniska A; Marshall KW; Mookerjee B; Nath R; Rapoport AP; Sarkodee-Adoo C; Takebe N; Vesole DH; Wagner JL; Flomenberg N
    Bone Marrow Transplant; 2004 Apr; 33(8):781-7. PubMed ID: 14767498
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trial of amifostine in autologous stem cell transplant.
    Sastry P; Bhagwat R; Biswas G; Khadwal A; Narayanan P; Bakshi A; Parikh P
    Bone Marrow Transplant; 2006 Jan; 37(1):117-8. PubMed ID: 16273114
    [No Abstract]   [Full Text] [Related]  

  • 45. Delayed neutrophil recovery after BEAM chemotherapy and autologous bone marrow transplantation for lymphoma is not associated with increased mortality from infection.
    Khwaja A; Goldstone AH; Linch DC
    Bone Marrow Transplant; 1995 Feb; 15(2):313-5. PubMed ID: 7773224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma.
    Leger C; Sabloff M; McDiarmid S; Bence-Bruckler I; Atkins H; Bredeson C; Zhang H; Huebsch L
    Ann Hematol; 2006 Oct; 85(10):723-9. PubMed ID: 16832675
    [TBL] [Abstract][Full Text] [Related]  

  • 47. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
    Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
    Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Effectiveness of high-dose polychemotherapy and autologous hemopoietic cell transplantation in patients with low-grade non-Hodgkin lymphoma].
    Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
    Vopr Onkol; 2002; 48(6):668-72. PubMed ID: 12530261
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Role of high-dose BEAM-chemotherapy and autologous hemopoietic stem cell transplantation in the treatment of drug-resistant Hodgkin disease].
    Uss AL; Zmachinskiĭ VA; Milanovich NF; Skriagin AE; Dziuba EV; Vlasenkova SV; Solov'eva NS; Batan ZE; Mitskevich PB; Zavgorodniaia IL; Aleĭnikova OV; Zhavrid EA
    Vopr Onkol; 2000; 46(5):619-23. PubMed ID: 11202200
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment of lymphoma relapses after allogeneic hematopoietic stem cell transplantation with intensive chemotherapy followed by infusion of hematopoietic stem cell from the original donor.
    Au WY; Lie AK; Siu LL; Chan EC; Ooi GC; Leung AY; Liang R; Kwong YL
    Ann Hematol; 2003 Sep; 82(9):548-51. PubMed ID: 14504811
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
    Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
    Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
    Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
    Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma.
    Nagler A; Slavin S; Varadi G; Naparstek E; Samuel S; Or R
    Bone Marrow Transplant; 2000 May; 25(10):1021-8. PubMed ID: 10828860
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
    Holmberg LA; Maloney DG; Connelly-Smith L
    Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase Ib clinical trial of PV701, a milk-derived protein extract, for the prevention and treatment of oral mucositis in patients undergoing high-dose BEAM chemotherapy.
    Prince HM; Regester G; Gates P; Jablonskis L; Seymour JF; Lillie K; West R; Wolf M; Januszewicz H; Belford D
    Biol Blood Marrow Transplant; 2005 Jul; 11(7):512-20. PubMed ID: 15983551
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunomagnetic selection of CD34(+) cells carried out in cryopreserved cell concentrates from a paediatric patient affected with non-Hodgkin lymphoma.
    Zinno F; Landi F; Aureli V; Cometa AM; Scerpa MC; Caniglia M; Pinto RM; Rana I; Balduino G; Miele MJ; Isacchi G
    Transfus Med; 2010 Aug; 20(4):283-6. PubMed ID: 20136780
    [No Abstract]   [Full Text] [Related]  

  • 57. Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy.
    Re D; Bamborschke S; Feiden W; Schröder R; Lehrke R; Diehl V; Tesch H
    Bone Marrow Transplant; 1999 Feb; 23(3):295-8. PubMed ID: 10084263
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Communication challenges in a young man with Hodgkin's disease.
    Medoff E
    Cancer Pract; 2001; 9(6):272-6. PubMed ID: 11879328
    [No Abstract]   [Full Text] [Related]  

  • 59. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study.
    Moreau P; Milpied N; Voillat L; Colombat P; Mahé B; Rapp MJ; Moreau A; Dupas B; Bulabois CE; Juge-Morineau N; Harousseau JL
    Bone Marrow Transplant; 1998 Jun; 21(12):1193-6. PubMed ID: 9674850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. BEAC or BEAM high-dose chemotherapy followed by autologous stem cell transplantation in non-Hodgkin's lymphoma patients: comparative analysis of efficacy and toxicity.
    Jo JC; Kang BW; Jang G; Sym SJ; Lee SS; Koo JE; Kim JW; Kim S; Huh J; Suh C
    Ann Hematol; 2008 Jan; 87(1):43-8. PubMed ID: 17710401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.